


*New Developments in Biotechnology: U.S.
Investment in Biotechnology*

July 1988

NTIS order #PB88-246939



Recommended Citation:

U.S. Congress, Office of Technology Assessment, New Developments *in Biotechnology: U.S. Investment in Biotechnology*—Special Report, OTA-BA-360 (Washington, DC: U.S. Government Printing Office, July 1988).

Library of Congress Catalog Card Number 88-600538

For sale by the Superintendent of Documents
U.S. Government Printing Office, Washington, DC 20402-9325
(order form can be found in the back of this report)

Foreword

Since the discovery of recombinant DNA in the early 1970s, biotechnology has become an essential tool for many industries. The potential of biotechnology to improve the Nation's health, food supply, and the quality of the environment leads logically to questions of whether current levels of investment in research and development, human resources, and policy formulation are adequate to meet these expectations.

This special report is the fourth in a series of OTA studies being carried out under an assessment of "New Developments in Biotechnology," requested by the House Committee on Energy and Commerce and the House Committee on Science, Space, and Technology. This fourth report in the series describes the levels and types of investment currently being made by the Federal, State, and private sectors. Ten major issues that affect investment were identified. They concern levels of R&D funding, research priorities, interagency coordination, information requirements, training and education needs, monitoring of university-industry research, State efforts to promote biotechnology, the effects of tax law on commercial biotechnology, the adequacy of Federal assistance for biotechnology start-ups, and the effects of export control on biotechnology commerce. The first publication in the series was *Ownership of Human Tissues and Cells*, the second was *Public Perceptions of Biotechnology*, and the third was *Field-Testing Engineered Organisms*. A subsequent study will examine issues relevant to patenting plants, animals, and micro-organisms.

OTA was assisted in preparing this study by a panel of advisors, four workshop groups, and reviewers selected for their expertise and diverse points of view on the issues covered in the report. OTA gratefully acknowledges the contribution of each of these individuals. As with all OTA reports, responsibility for the content of the special report is OTA's alone. The special report does not necessarily constitute the consensus or endorsement of the advisory panel, the workshop groups, or the Technology Assessment Board.



JOHN H. GIBBONS
Director

New Developments in Biotechnology Advisory Panel

Bernadine P. Healy, *Panel Chair*
The Cleveland Clinic Foundation
Cleveland, OH

Timothy B. Atkeson
Steptoe & Johnson
Washington, DC

David Blumenthal
Brigham and Women's Hospital Corp.
Cambridge, MA

Hon. Edmund G. Brown, Jr.
Reavis & McGrath
Los Angeles, CA

Nancy L. Buc
Weil, Gotshal & Manges
Washington, DC

Mark F. Cantley
Concertation Unit for Biotechnology in Europe
Brussels, Belgium

Alexander M. Capron
University of Southern California
Los Angeles, CA

Jerry D. Caulder
Mycogen Corp.
San Diego, CA

Lawrence I. Gilbert
The University of North Carolina
Chapel Hill, NC

Conrad A. Istock
The University of Arizona
Tucson, AZ

Edward L. Korwek
Hogan & Hartson
Washington, DC

Tsune Kosuge*
University of California, Davis
Davis, CA

Richard Krasnow
Institute for International Education
Washington, DC

Sheldon Krinsky
Tufts University
Medford, MA

Joshua Lederberg
The Rockefeller University
New York, NY

William E. Marshall
Pioneer Hi-Bred International, Inc.
Johnston, IA

Ronald L. Meeusen
Sandoz Crop Protection Corp.
Palo Alto, CA

Robert B. Nicholas
Nash, Railsback, and Plesser
Washington, DC

Eric J. Stanbridge
University of California, Irvine
Irvine, CA

James M. Tiedje
Michigan State University
East Lansing, MI

Kynio Toriyama
Nat. Fed. of Agri. Coop. Assn. of Japan
Tokyo, Japan

Pablo D.T. Valenzuela
Chiron Corp.
Emeryville, CA

Thomas E. Wagner
Ohio University
Athens, OH

*Resigned February 1988.

NOTE: OTA is grateful for the valuable assistance and thoughtful critiques provided by the Advisory Panel members. The views expressed in this OTA report, however, are the sole responsibility of the Office of Technology Assessment.

OTA Project Staff
NEW DEVELOPMENTS IN BIOTECHNOLOGY: U.S. INVESTMENT

Roger C. Herdman, *Assistant Director, OTA Health and Life Sciences Division*

Gretchen S. Kolsrud, *Biological Applications Program Manager*

Gary B. Ellis, *Project Director*

Kathi E. Hanna, *Study Director*

Patricia J. Hoben, *Analyst*

Robyn Y. Nishimi, *Analyst*

Blake M. Cornish, *Research Analyst*

Margaret A. Anderson, *Contractor*

Barbara R. Williams, National Institutes of Health, *Professional Development Trainee*

Editor

Stephanie Forbes, Bowie MD

Support Staff

Sharon Kay Oatman, *Administrative Assistant*

Linda S. Rayford, *Secretary/Word Processing Specialist*

Barbara V. Ketchum, *Clerical Assistant*

Contractors

Center for Survey Research, Boston, MA

Jack Doyle, Environmental Policy Institute, Washington, DC

Richard A. Herrett, Washington, DC

Jeffrey Mervis, Washington, DC

North Carolina Biotechnology Center, Research Triangle Park, NC

Richard J. Patterson, Research Triangle Park, NC

Solomon Associates, Washington, DC

William G. Wells, George Washington University, Washington, DC